Weight-loss drug developers line up to tap lucrative market as competition heats up

The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...
Wellbeing Whisper on MSN

Eli Lilly lowers Zepbound vial prices amid intensifying GLP-1 competition

The steep monthly costs of GLP-1 medications have long been a major obstacle for many patients trying to find effective ...
Devdiscourse

Race in Obesity Drugs Heats Up Amidst Legal Battles and Aid Crises

Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...

Lilly Cuts Low-Dose Zepbound Price for Cash-Pay Buyers

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up ...
The Pharma Letter

Lilly cuts Zepbound vial prices as obesity drug competition heats up

US pharma major Eli Lilly (NYSE: LLY) has lowered the price of Zepbound (tirzepatide) single-dose vials on its Lilly Direct ...
KTVU

Trump announces price cuts on Wegovy, Zepbound

President Donald Trump announced a new agreement with Eli Lilly and Novo Nordisk to expand coverage and lower prices for popular obesity drugs Zepbound and Wegovy, part of the GLP-1 class of ...
Zacks.com on MSN

LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website

Eli Lilly LLY announced that it has lowered the price of single-dose vials of its blockbuster obesity drug, Zepbound ...
Becker's Hospital Review

Eli Lilly reduces Zepbound price

Eli Lilly has lowered the price of its GLP-1 drug Zepbound (tirzepatide) in single-dose vials, with the starting dose now available for $299 per month through the company’s direct-to-consumer platform ...

Market Voices: Trump on Fed chair, US-UK pharma deal, Lilly's Zepbound

Seeking Alpha's roundup of statements, announcements, and remarks that could impact markets, sectors, or individual stocks. Read more here.